WO2019093717A3 - Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물 - Google Patents

Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물 Download PDF

Info

Publication number
WO2019093717A3
WO2019093717A3 PCT/KR2018/013220 KR2018013220W WO2019093717A3 WO 2019093717 A3 WO2019093717 A3 WO 2019093717A3 KR 2018013220 W KR2018013220 W KR 2018013220W WO 2019093717 A3 WO2019093717 A3 WO 2019093717A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
diagnosing
lung cancer
cancer based
marker composition
Prior art date
Application number
PCT/KR2018/013220
Other languages
English (en)
French (fr)
Other versions
WO2019093717A2 (ko
Inventor
김현구
홍성회
박용
최연호
박지호
최병현
정혜선
Original Assignee
고려대학교 산학협력단
한국과학기술원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고려대학교 산학협력단, 한국과학기술원 filed Critical 고려대학교 산학협력단
Priority to JP2020524788A priority Critical patent/JP6908785B2/ja
Priority to US16/762,140 priority patent/US20210018505A1/en
Priority to CN201880072074.2A priority patent/CN111373056A/zh
Publication of WO2019093717A2 publication Critical patent/WO2019093717A2/ko
Publication of WO2019093717A3 publication Critical patent/WO2019093717A3/ko
Priority to US17/539,030 priority patent/US12000832B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

본 발명의 일 실시예에 따르면, 엑소좀(exosome) 내 GCC2(GRIP and coiled-coil domain-containing protein) 유전자 또는 단백질에 특이적으로 결합하는 프라이머, 프로브 또는 항체를 포함하는, 폐암 진단 또는 예후 예측용 조성물이 제공된다.
PCT/KR2018/013220 2017-11-07 2018-11-02 Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물 WO2019093717A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2020524788A JP6908785B2 (ja) 2017-11-07 2018-11-02 Ｇｃｃ２遺伝子又はタンパク質を過発現するエクソソーム基盤肺癌診断又は予後予測用マーカー組成物
US16/762,140 US20210018505A1 (en) 2017-11-07 2018-11-02 Marker composition for diagnosing or predicting prognosis of lung cancer based on exosome overexpressing gcc2 gene or protein
CN201880072074.2A CN111373056A (zh) 2017-11-07 2018-11-02 基于过表达gcc2基因或蛋白的外泌体的用于诊断肺癌或预测预后的标志物组合物
US17/539,030 US12000832B2 (en) 2017-11-07 2021-11-30 Marker composition for diagnosing or predicting prognosis of lung cancer based on exosome overexpressing GCC2 gene or protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170147510A KR102080887B1 (ko) 2017-11-07 2017-11-07 Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물
KR10-2017-0147510 2017-11-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/762,140 A-371-Of-International US20210018505A1 (en) 2017-11-07 2018-11-02 Marker composition for diagnosing or predicting prognosis of lung cancer based on exosome overexpressing gcc2 gene or protein
US17/539,030 Division US12000832B2 (en) 2017-11-07 2021-11-30 Marker composition for diagnosing or predicting prognosis of lung cancer based on exosome overexpressing GCC2 gene or protein

Publications (2)

Publication Number Publication Date
WO2019093717A2 WO2019093717A2 (ko) 2019-05-16
WO2019093717A3 true WO2019093717A3 (ko) 2019-06-27

Family

ID=66438917

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/013220 WO2019093717A2 (ko) 2017-11-07 2018-11-02 Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물

Country Status (5)

Country Link
US (2) US20210018505A1 (ko)
JP (1) JP6908785B2 (ko)
KR (1) KR102080887B1 (ko)
CN (1) CN111373056A (ko)
WO (1) WO2019093717A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102350603B1 (ko) 2019-04-03 2022-01-14 고려대학교 산학협력단 Tuba1c 단백질을 과발현하는 엑소좀 기반 암 진단 또는 예후 예측용 마커 조성물
KR102318328B1 (ko) * 2020-04-13 2021-10-27 고려대학교 산학협력단 Gcc2 단백질을 과발현하는 엑소좀 기반 암 진단 또는 예후 예측용 마커 조성물
KR20230084704A (ko) 2021-12-06 2023-06-13 주식회사 엑소퍼트 Gcc2 억제제를 유효성분으로 포함하는 폐암 예방 또는 치료용 조성물
KR20240017323A (ko) 2022-07-29 2024-02-07 고려대학교 산학협력단 Gcc2 발현 억제제를 유효성분으로 포함하는 폐암 예방또는 치료용 약학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110038801A1 (en) * 2007-12-21 2011-02-17 Biosante Pharmaceuticals, Inc. Methods and compositions for identifying lung cancer or a humoral immune response against lung cancer
WO2017181183A1 (en) * 2016-04-15 2017-10-19 Exosome Diagnostics, Inc. Plasma-based detection of anaplastic lymphoma kinase (alk) nucleic acids and alk fusion transcripts and uses thereof in diagnosis and treatment of cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871774B2 (en) 2005-01-31 2011-01-18 Digital Genomics Inc. Markers for the diagnosis of lung cancer
KR100690250B1 (ko) 2005-01-31 2007-03-12 디지탈 지노믹스(주) 폐암 진단용 마커
WO2007026896A1 (ja) * 2005-09-02 2007-03-08 Toray Industries, Inc. 腎ガン診断、腎ガン患者予後予測のための組成物および方法
JP5580205B2 (ja) 2007-11-19 2014-08-27 セレラ コーポレーション 肺癌マーカーとその使用
US20120058492A1 (en) * 2008-01-25 2012-03-08 Hansabiomed Ou Method and a Kit To Detect Malignant Tumors and Provide a Prognosis
CN107254538A (zh) * 2008-11-12 2017-10-17 卡里斯生命科学瑞士控股有限责任公司 使用外来体来确定表现型的方法和系统
WO2010115077A2 (en) * 2009-04-02 2010-10-07 The Johns Hopkins University Biomarker panels for barrett's esophagus and esophageal adenocarcinoma
WO2010131193A1 (en) * 2009-05-12 2010-11-18 Koninklijke Philips Electronics N.V. Phosphodiesterase 9a as prostate cancer marker
JP6148007B2 (ja) * 2009-05-12 2017-06-14 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７
KR101292163B1 (ko) 2010-11-23 2013-08-12 한양대학교 산학협력단 Ｋｒｔ１９ 항체를 포함하는 항암용 조성물
WO2012135844A2 (en) * 2011-04-01 2012-10-04 Cornell University Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers
PE20142322A1 (es) * 2012-04-27 2015-01-25 Millennium Pharm Inc Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc
KR101680360B1 (ko) 2014-01-22 2016-11-28 주식회사 엑쏘좀 Del-1 단백질 양성 엑소좀을 포함하는 암 진단 또는 예후 예측용 조성물
KR20160133740A (ko) * 2015-05-13 2016-11-23 경북대학교 산학협력단 파이브로넥틴 단백질 양성 엑소좀을 포함하는 암 진단 또는 예후 예측용 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110038801A1 (en) * 2007-12-21 2011-02-17 Biosante Pharmaceuticals, Inc. Methods and compositions for identifying lung cancer or a humoral immune response against lung cancer
WO2017181183A1 (en) * 2016-04-15 2017-10-19 Exosome Diagnostics, Inc. Plasma-based detection of anaplastic lymphoma kinase (alk) nucleic acids and alk fusion transcripts and uses thereof in diagnosis and treatment of cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JIANG, JUNHONG: "GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors", LUNG CANCER, vol. 115, pages 5 - 11, XP085321461 *
NOH, KA-WON: "Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearraned non?small cell lung cancer", THE JOURNAL OF PATHOLOGY, vol. 243, no. 3, 1 November 2017 (2017-11-01), pages 307 - 319, XP055456836 *
VENDRELL, JULIE A.: "Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches", vol. 7, no. 12510, 2 October 2017 (2017-10-02), pages 1 - 11, XP055621977 *

Also Published As

Publication number Publication date
KR20190051641A (ko) 2019-05-15
US20220196664A1 (en) 2022-06-23
CN111373056A (zh) 2020-07-03
US12000832B2 (en) 2024-06-04
US20210018505A1 (en) 2021-01-21
WO2019093717A2 (ko) 2019-05-16
KR102080887B1 (ko) 2020-02-24
JP6908785B2 (ja) 2021-07-28
JP2021501897A (ja) 2021-01-21

Similar Documents

Publication Publication Date Title
WO2019093717A3 (ko) Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물
WO2018187496A8 (en) PLASMA PROTEIN PROFILING FOR THE EARLY PROGNOSIS OF LUNG CANCER
MY197854A (en) Antibodies against signal-regulatory protein alpha and methods of use
WO2018213604A3 (en) DIAGNOSTIC ASSAYS FOR DETECTING, QUANTIFYING AND / OR FOLLOWING MICROBES AND OTHER ANALYTES
WO2007114947A3 (en) Highly sensitive system and methods for analysis of troponin
BR112016002845A2 (pt) composições e métodos para tratar condições associadas ao complemento
WO2017106684A3 (en) Antibodies specifically binding hla-dr and their uses
WO2019236749A3 (en) Methods and applications of protein identification
WO2019099597A3 (en) Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof
AU2018336160A1 (en) Sex-linked genomic marker for crayfish and uses thereof
MX2022007706A (es) Anticuerpos utiles en diagnosis de cancer.
EP4022094A4 (en) BIOMARKERS FOR DIAGNOSIS OF LUNG CANCER
EP3740590A4 (en) LUNG CANCER DIAGNOSIS KITS AND METHODS
EP4180814A3 (en) Markers of endometrial cancer
WO2008104985A3 (en) Methods for distingushing between lung squamous carcinoma and other non smallcell lung cancers
EP3844506A4 (en) PROTEIN NANOPORES FOR IDENTIFICATION OF AN ANALYTE
EP4220171A3 (en) Markers for endometrial cancer
CA3080263A1 (en) Method for diagnosing cancer from blood
WO2020252394A3 (en) Targets and methods of diagnosing, monitoring and treating frontotemporal dementia
NZ751193A (en) Protein biomarkers for diseases associated with the contact activation system
WO2019060915A3 (en) Multiplexed protein assay for the detection of mitochondrial protein signatures
WO2017156038A3 (en) Immunoassay controls and the use thereof
EP3315613A3 (en) Methods and kits for diagnosing or assessing the risk of cervical cancer
EP3850348A4 (en) METHODS, REAGENTS AND SUBSTRATES FOR THE DETECTION OF TARGET ANALYTES
MX2019005940A (es) Biomarcadores relacionados a cancer.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18877038

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020524788

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18877038

Country of ref document: EP

Kind code of ref document: A2